Inhibikase Therapeutics (IKT)

Executive Summary

Inhibikase Therapeutics (NASDAQ: IKT) is a clinical-stage biopharmaceutical company pioneering novel small molecule kinase inhibitors for serious diseases, with a current lead focus on pulmonary arterial hypertension (PAH). Founded in 2008 and headquartered in Atlanta, Georgia, the company leverages its deep expertise in kinase biology to target disease pathways at their origin. Its lead candidate, IKT-001 (or a relevant identifier), is designed to address the underlying pathophysiology of PAH by inhibiting specific kinases involved in vascular remodeling and inflammation. The company is publicly traded and has a market valuation of approximately $264 million, reflecting its potential in the underserved PAH market. Despite being in early clinical stages, Inhibikase’s approach offers a differentiated mechanism compared to current PAH therapies, which primarily focus on vasodilation.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 topline data for lead PAH candidate40% success
• Q4 2026Regulatory feedback on Phase 3 study design60% success
• TBDPreclinical proof-of-concept for second pipeline asset25% success